Terray Therapeutics

Terray reports scientists using EMMI daily for molecule generation, prediction and selection, linked to automated synthesis and testing, with over 13 billion measured target-molecule interactions.

Terray achieved a drug-discovery milestone in its multi-target collaboration with Bristol Myers Squibb and also works with Gilead, Calico and Odyssey, but downstream clinical impact remains early.

Terray achieved a drug-discovery milestone in its multi-target collaboration with Bristol Myers Squibb and also works with Gilead, Calico and Odyssey, but downstream clinical impact remains early.

Terray develops the EMMI platform integrating custom experimental hardware, a 13B+ target-ligand binding dataset, generative AI and automated chemistry, including TerraBind and TerraSynth.

Terray develops the EMMI platform integrating custom experimental hardware, a 13B+ target-ligand binding dataset, generative AI and automated chemistry, including TerraBind and TerraSynth.

Terray built EMMI as a closed-loop drug-discovery platform combining proprietary experimental hardware, internally generated datasets and full-stack AI, linking high-throughput physical experimentation directly with machine intelligence for small-molecule discovery.

Terray describes an operational software layer that connects AI molecule design to automated laboratory experiments and returns experimental data to subsequent model/design iterations; it reports daily internal and partnered pipeline use.

Terray has more than $200M in total equity financing and strategic collaborations with major pharmaceutical partners while building proprietary lab, data and AI infrastructure.

Terray has more than $200M in total equity financing and strategic collaborations with major pharmaceutical partners while building proprietary lab, data and AI infrastructure.

TerraSynth represents synthesis routes as autoregressive sequences with COATI molecular representations and uses reinforcement-learning rewards to penalize chemically inconsistent routes. This provides concrete experience in sequence modeling and reward optimization that can transfer to other generative-AI systems.

ML, generative chemistry and lab automation skills transfer strongly within TechBio and drug discovery, but chemistry and wet-lab specialization limit full cross-market portability.

ML, generative chemistry and lab automation skills transfer strongly within TechBio and drug discovery, but chemistry and wet-lab specialization limit full cross-market portability.